本地生产ACWY群脑膜炎球菌疫苗Ingovax ACWY在孟加拉国成人中的3期非劣效性试验
在88名18-45岁健康成人中开展随机观察者盲法非劣效性试验,按1:1皮下接种单剂Ingovax ACWY(试验疫苗)或Quadri MeningoTM(对照疫苗)。两组不良事件率无显著差异,最常见为注射部位疼痛,无严重不良事件。试验疫苗与对照疫苗的血清转换率及免疫前后SBA GMT均无显著差异(p<0.05),各血清群GMR的95%CI下限均大于预设0.5非劣效界值,表明免疫原性与安全性非劣效。
要点
- 两组不良事件率无显著差异,最常见为注射部位疼痛,无严重不良事件报告。
- 试验与对照疫苗血清转换率及接种前后SBA GMT均无显著差异(p<0.05)。
- A、C、W135、Y群GMR分别为0.9、1、1.29、0.85,95%CI下限均大于0.5非劣效界值。
核心结论
- Ingovax ACWY的免疫原性与安全性非劣效于对照疫苗Quadri MeningoTM。
- 本地生产多糖ACWY疫苗设施的建设将促进孟加拉国疫苗领域的能力建设。
研究设计与样本
- 随机观察者盲法非劣效性试验,共纳入88名18-45岁健康成人,按1:1随机分为试验疫苗组和对照疫苗组,皮下接种单剂疫苗。
- 所有参与者随访至接种后三个月,接种前及接种后一个月采集血液用于临床参数(血液学和生化)及血清杀菌试验(SBA)。
- 征集性不良事件评估至接种后6天,非征集性不良事件在整个随访期间监测。
主要发现
- 两组不良事件率无显著差异,最常见征集性不良事件为注射部位疼痛,未报告严重不良事件。
- 试验疫苗与对照疫苗的血清转换率及接种前后SBA几何平均滴度(GMT)均无显著差异(p<0.05)。
- 试验疫苗与对照疫苗的接种后GMT比值(GMR)在A、C、W135、Y血清群分别为0.9、1、1.29、0.85。
- 所有血清群GMR的95%CI下限均大于预设的0.5非劣效界值,提示Ingovax ACWY与Quadri MeningoTM相似。
关键数值与推荐
- 非劣效界值预设为GMR的95%CI下限大于0.5。
- A、C、W135、Y群接种后GMR分别为0.9、1、1.29、0.85,各群95%CI下限均大于0.5。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningococcal disease is caused by Neisseria meningitidis or meningococcus. Every year globally around 1.2 million people are affected and approximately 120,000 deaths occur due to meningitis. The disease can be prevented by a single dose of meningococcal vaccine. We carried out a randomized observer-blinded non-inferiority trial to evaluate and compare the immunogenicity and safety of a local meningococcal polysaccharide vaccine 'Ingovax ACWY' (test) with Quadri MeningoTM (comparator), an approved meningococcal polysaccharide vaccine in India. A total of 88 healthy adults (18-45 years old) were randomized at a 1:1 ratio in two vaccine groups receiving a single dose vaccine subcutaneously. All participants were followed until three months post-vaccination. Blood for clinical parameters (hematology and biochemistry) and serum bactericidal assay (SBA) was collected prior to vaccination and one-month post-vaccination. Solicited adverse events (AEs) were assessed up to 6 days following vaccination and unsolicited AEs were monitored throughout the follow-up period. There was no significant difference in rates of AE between the two groups. The commonest solicited AE was injection site pain. No serious AEs were reported. There was no significant difference (p<0.05) in seroconversion rate as well as pre and post-vaccination SBA geometric mean titers (GMT)between test and comparator vaccine. The post-vaccination GMT ratio (GMR) of the test and comparator vaccine was found to be 0.9, 1, 1.29, and 0.85 for serogroup A, C, W135, and Y respectively. For all the serogroups, lower limit of 95% CI of the GMR was found to be greater than the pre-defined 0.5 non-inferiority margin suggesting that Ingovax ACWY is similar to Quadri MeningoTM vaccine. We observed the immunogenicity and safety of Ingovax ACWY is non-inferior to comparator vaccine. The development of facilities for manufacturing polysaccharide ACWY vaccines locally will further lead to capacity building in the field of vaccines for Bangladesh.
引用
- Ahmed T, Tauheed I, Hoque S, et al. A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults. Vaccine. 2024. PMID: 38897895. doi:10.1016/j.vaccine.2024.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。